During the last few years several clinical guidelines on attention-deficit hyperactivity disorder (ADHD) have been published by national and international medical societies. To systematically review and compare recommendations of selected ADHD guidelines, we performed a systematic search in online guideline databases and PubMed in order to retrieve guideline texts. Guidelines meeting inclusion criteria were reviewed and recommendations on assessment and treatment extracted. The AGREE instrument was used to assess methodological quality. Of the 26 guidelines identified, 13 were selected for further analysis: 11 guidelines deal with ADHD in childhood and adolescence and 5 guidelines cover transitional patients and/or ADHD in adults. The methodological quality of ADHD guidelines is moderate to good. They reflect similarities and differences of healthcare systems. Diagnosis throughout the lifespan is based on a detailed clinical history. There is greater agreement on evidence-based pharmacological treatment than on psychosocial interventions, reflecting the strength of evidence.
AGREE Collaboration (2003) Development and validation of an internal appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Qual Saf Health Care12: 18–23.
2.
American Academy of Pediatrics (AAP), Committee on Quality Improvement Subcommittee on Attention-Deficit / Hyperactivity Disorder (2000) Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics105: 1158–1170.
3.
American Academy of Pediatrics (AAP), Committee on Quality Improvement, Subcommittee on Attention-Deficit / Hyperactivity Disorder (2001) Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics108: 1033–1044.
4.
American Psychiatric Association (APA) (2000) Diagnostic and Statistical Manual of Mental Disorders version IV – text revision. Washington DC: American Psychiatric Association.
5.
AugustGRealmutoG (2000) Pharmacotherapy in ADHD: Guidelines for prescribing stimulant medications in young children. Minn Med83: 45–46.
6.
BanaschewskiTCoghillDSantoshPZuddasAAshersonPBuitelaarJ. (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry15: 476–495.
7.
BanaschewskiTCoghillDSantoshPZuddasAAshersonPBuitelaarJ. (2008) Langswirksame Medikamente zur Behandlung der hyperkinetischen Störungen: Eine systematische Übersicht und europäische Behandlungsleitlinien. Teil 1: Übersicht und Empfehlungen / Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. Z Kinder Jugendpsychiatr Psychotherap36: 81–95/97–107.
8.
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD Practice Guidelines, Third Edition. Toronto, Ontario: CADDRA.
9.
Cincinnati Children’s Hospital Medical Center (2004) Evidence based clinical practice guideline for outpatient evaluation and management of attention deficit/hyperactivity disorder. Cincinnati, OH: Cincinnati Children’s Hospital Medical Center.
10.
Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie (2007) Hyperkinetische Störungen (F90). In Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. 3. überarbeitete Auflage. Cologne: Deutscher Ärzte Verlag.
11.
EbertDKrauseJRoth-SackenheimC (2003) ADHS im Erwachsenenalter - Leitlinien auf der Basis eines Expertenkonsensus mit Unterstützung der DGPPN. Nervenarzt74: 939–946.
12.
FayyadJDe GraafRKesslerRAlonsoJAngermeyerMDemyttenaereK. (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry190: 402–409.
13.
FordTGoodmanRMeltzerH (2003) The British Child and Adolescent Mental Health Survey 1999: The prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry42: 1203–1211.
14.
GreenhillLLPliszkaSDulcanMKBernetWArnoldVBeitchmanJ. (American Academy of Child and Adolescent Psychiatry) (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry41: 26S–49S.
15.
HayashiKTanakaHMiyajimaTSaitoKKodairaKYamashitaY (2006) Advance in diagnosis and management guideline of AD/HD (attention deficit/hyperactivity disorder) for pediatricians in Japan. No to Hattatsu38: 141–143.
16.
HuttinC (1997) The use of clinical guidelines to improve medical practice: Main issues in the United States. Int J Qual Health Care9: 207–214.
17.
HvolbyAJørgensenJI (2004) Treatment with central nervous system stimulants. Practical guideline. Ugeskr Laeger166: 144–148.
18.
Institute for Clinical Systems Improvement (2010) Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents, 8th Edition.Bloomington, Minn: Institute for Clinical Systems Improvement (ICSI).
19.
KesslerRCAdlerLBarkleyRBiedermanJConnersCKDemlerO. (2006) The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry163: 716–723.
20.
KooijSJBegerotSBlackwellACaciHCasas-BruguéMCarpentierPJ. (2010) European Consensus Statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry10: 67.
21.
KutcherSAmanMBrooksSJBuitelaarJvan DaalenEFegertJ. (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol14: 11–12.
22.
McCabeSETeterCJBoydCJ (2006) Medical use, illicit use and diversion of prescription stimulant medication. J Psychoact Drugs38: 43–56.
23.
McGoughJJ (2005) Adult manifestations of attention deficit/hyperactivity disorder. In: SadockBJSadockVA (eds) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 8th Edition. Philadelphia, PA: Lippincott Williams & Wilkins.
24.
MüllerUWolfHKieferMGertzHJ (2003) [A systematic comparison of national and international dementia guidelines]. Fortschr Neurol Psychiatr71: 285–295.
25.
National Institute for Health and Clinical Excellence (NICE) (2008) Attention Deficit Hyperactivity Disorder – Diagnosis and Management of ADHD in Children, Young People and Adults. NICE clinical guideline 72. London: The British Psychological Society and The Royal College of Psychiatrists.
26.
National Institute for Health and Clinical Excellence (NICE) (2006) Methylphenidate, Atomoxetine and Dexamfetamine for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents. Review of Technology Appraisal 13. London: National Institute for Health and Clinical Excellence.
27.
National Institutes of Health (1998) Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consens Statement OnlineNov16–18; 16: 1–37.
28.
National Institutes of Health (2000) National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry39: 182–193.
29.
New Zealand Ministry of Health (2001) New Zealand Guidelines for the Assessment and Treatment of Attention-Deficit/Hyperactivity Disorder. Wellington: Ministry of Health.
30.
NuttDJFoneKAshersonPBrambleDHillPMatthewsK. British Association for Psychopharmacology (2006) Evidence-based guidelines for management of attention deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol21: 10–41.
31.
PliszkaS; American Academy of Child and Adolescent Psychiatry (AACAP) Work Group on Quality Issues (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry46: 894–921.
32.
PliszkaSRCrismonMLHughesCWCornersCKEmslieGJJensenPS. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder (2006) The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry45: 642–657.
33.
PliszkaSRLopezMCrismonMLTopracMGHughesCWEmslieGJBoemerC (2003) A feasibility study of the children’s medication algorithm project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry42: 279–287.
34.
PolanczykGDe LimaMSHortaBLLiebermanJRohdeLA (2007) The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry164: 942–948.
35.
RemschmidtH; Global ADHD Working Group (2005) Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry14: 127–137.
36.
Retz-JungingerPRetzWBlocherDWeijersHGTrottGEWenderPHRösslerM (2002) [Wender Utah rating scale. The short version for the assessment of the attention-deficit hyperactivity disorder in adults]. Nervenarzt73: 830–838.
37.
Roy-ByrnePScheeleLBrinkleyJWardNWiatrakCRussoJ. (1997) Adult attention-deficit hyperactivity disorder: Assessment guidelines based on clinical presentation to a specialty clinic. Compr Psychiatry38: 133–140.
38.
SafrenSASprichSMimiagaMJSurmanCKnouseLGrovesMOttoMW (2010) Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: A randomized controlled trial. JAMA304: 875–880.
39.
SaitoM (2005) Diagnosis and therapeutic guideline for attention deficit hyperactivity disorder. Seishin Shinkeigaku Zasshi107: 167–179.
40.
Scottish Intercollegiate Guidelines Network (SIGN) (2009) Management of Attention Deficit and Hyperactivity Disorders in Children and Young People – A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN).
41.
SolantoMVMarksDJWassersteinJMitchellKAbikoffHAlvirJMKofmanMD (2010) Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry167: 958–968.
42.
TaylorEDöpfnerMSergeantJAshersonPBanaschewskiTBuitelaarJ. (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry13: 17–30.
43.
The MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry56: 1073–1086.
44.
University of Michigan Health System (2005) Attention-deficit hyperactivity disorder. Ann Harbor, MI: University of Michigan Health System.
45.
WardMFWenderPHReimherrFW (1993) The Wender Utah Rating Scale: An aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry150(6): 885–890.
46.
WilensTEGignacMSwezeyAMonuteauxMCBiedermanJ (2006) Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry45: 408–414.
47.
WolraichMLBardDESteinMTRushtonJLO’ConnorKG (2010) Pediatricians’ attitudes and practices on ADHD before and after the development of ADHD pediatric practice guidelines. J Atten Disord13: 563–572.
48.
WongMAtkinsDTaylorJFeinleibM (1999) Diagnosis of Attention-Deficit/Hyperactivity Disorder. Rockville, MD: Agency for Healthcare Policy and Research.
49.
WoolfSHGrolRHutchinsonAEcclesMGrimshawJ (1999) Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ318: 527–530.
50.
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
